Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Olgotrelvir on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Olgotrelvir is an oral antiviral capsule for COVID-19, developed and made in China by Zhejiang ACEA Pharmaceutical, where it is sold as 奥维宁® (olgotrelvir sodium capsules). It is a short, five-day course, taken on its own, without a second "booster" medicine.
China's National Medical Products Administration (NMPA) gave it conditional approval in late October 2025 (announced 5 November 2025) for:
Conditional approval means the company must still submit further study results to the NMPA. The Chinese label also points out that the virus keeps changing, so doctors should take the variants in circulation into account.
It is a prescription infectious disease medicine and should only be used under a doctor's care.
Once swallowed, olgotrelvir is turned into its active form, AC1115. This blocks the virus's main protease (Mpro, also called 3CL protease), an enzyme the virus needs to build new copies of itself. It also blocks cathepsin L, a protein in our own cells that the virus uses to get inside them. Acting on two targets at once is why the company describes it as a dual-action antiviral.
The phase 3 trial (MPR-COV-301CN), published in NEJM Evidence in 2024, enrolled 1,212 adults in China with mild or moderate COVID-19 who were not in hospital. Most were young (median age 33), vaccinated and had mild illness.
It has not been studied in people with liver or kidney problems, or in anyone under 18. Your doctor decides whether it is suitable for you.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Allergy: it must not be taken by anyone allergic to olgotrelvir or any of the capsule's ingredients. The capsules contain sodium bisulfite, so people who are sensitive to sulfites should use them with caution.
Side effects in the trial: side effects judged to be caused by the medicine occurred in 14.2% of people on olgotrelvir and 9.2% on placebo, and 97.7% of them were mild or moderate. The most common were raised triglycerides (blood fats, 3.1% vs 2.0%), skin rash (2.5% vs 0%) and nausea (1.3% vs 0.2%). No serious side effects linked to the medicine and no deaths were reported.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit. Because the course should start within three days of symptoms, we tell you the realistic delivery time before you order.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. We also help with other imported antivirals, such as Livtencity and Foscavir, which are used for different viral infections.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each box holds 30 capsules of 0.2 g (five blister strips of six), which is exactly one full five-day course. The capsules are kept sealed, away from light and below 25°C, and travel in their original packs under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid doctor's prescription.
Being close to our New Delhi dispatch point gives patients in the capital the shortest delivery time, which matters for a medicine that should be started early.
Physicians in Mumbai can send the prescription and test report, and we confirm the delivery date before the order is placed.
Patients in Bangalore can have the single-box course delivered to their home or treating clinic once the papers are checked.
Infectious disease specialists in Chennai can request the capsules for a named patient through the same documented route.
We share a clear timeline with Hyderabad patients up front, so the doctor can judge whether it will arrive in time.
For Kolkata and the eastern states, the sealed packs are shipped below 25°C and away from light.
Patients in Pune get updates at each step, from document check to doorstep delivery.
Doctors in Ahmedabad can coordinate access for adults with mild or moderate COVID-19 who need this specific medicine.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating clinic.
Patients across Rajasthan can receive the capsules without travelling, as long as the import is in their name.
We coordinate delivery to patients and hospitals across Uttar Pradesh after the prescription is verified.
Patients across Kerala can have the course delivered to their home or clinic in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
